NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today stated that it was disappointed that the lawsuit filed last year by PharmAthene over its failure to consummate a licensing transaction with SIGA was not dismissed without discovery. The company further stated that it remains confident that PharmAthene's claim will ultimately not prevail and that SIGA will defend the matter vigorously.
